List clinical trials by disease

Clinical Trials

List clinical trials by disease

The results of your search are listed below. To view the details of a trial or study, click on the "SEE DETAILS" button. Or start a new search.

Searched for: Leukemia. 85 results shown below.
Feasibility and Outcomes of Allogeneic HCT Compared to Chemotherapy in Older AML Patients
Complete title: Feasibility and Outcomes of Allogeneic Hematopoietic Cell Transplantation (HCT) Compared to Conventional Therapy for Older and Medically Infirm Patients Diagnosed with Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes: A Prospective Observational Study

Principal Investigator: Mohamed Sorror, MD, MSc

Study Number: 2368.00

Phase: NA



Clofarabine and Low-Dose Total-Body Irradiation in Treating Patients With Acute Myeloid Leukemia Undergoing Donor Peripheral Blood Stem Cell Transplant
Complete title: A Phase II Study of Optimally Dosed Clofarabine in Combination with Low-Dose TBI to Decrease Relapse Rates after Related or Unrelated Donor Hematopoietic Cell Transplantation in Patients with AML

Principal Investigator: Brenda Sandmaier, MD

Study Number: 2430.00

Phase: II



Laboratory-Treated T Cells in Treating Patients With High-Risk Relapsed Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia Previously Treated With Donor Stem Cell Transplant
Complete title: Phase I/II Study of Adoptive Immunotherapy with Virus Specific CD8+ T Cells that have been Transduced to Express a WT1-Specific T Cell Receptor for Patients with Relapsed AML

Principal Investigator: Daniel Egan

Study Number: 2498.00

Phase: I/II



Donor Umbilical Cord Blood Transplant With or Without Ex-Vivo Expanded Cord Blood Progenitor Cells in Treating Patients With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia, or Myelodysplastic Syndromes
Complete title: Multi-Center, Open-Label Randomized Study of Single or Double Myeloablative Cord Blood Transplantation with or without Infusion of Off–the-Shelf Ex Vivo Expanded Cryopreserved Cord Blood Progenitor Cells in Patients with Hematologic Malignancies

Principal Investigator: Filippo Milano

Study Number: 2603.00

Phase: II



Chemotherapy in Treating Patients With Myelodysplastic Syndrome Before Donor Stem Cell Transplant (ICT-HCT)
Complete title: Initial Cytoreductive Therapy for Myelodysplastic Syndrome prior to Allogeneic Hematopoietic Cell Transplantation (the ICT-HCT Study)

Principal Investigator: Bart Scott, MD

Study Number: 2661.00

Phase: II



Filgrastim, Cladribine, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With Newly Diagnosed or Relapsed/Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes
Complete title: A Phase 1/2 Trial of G-CSF, Cladribine, Cytarabine, and Dose-Escalated Mitoxantrone (G-CLAM) in Adults with Newly Diagnosed or Relapsed/Refractory Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndromes (MDS)

Principal Investigator: Roland Walter, MD

Study Number: 2734.00

Phase: I/II



Outpatient Induction Chemotherapy in Treating Patients With Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome
Complete title: Feasibility of Outpatient Induction Chemotherapy for Adult Patients with Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome

Principal Investigator: Pamela Becker, MD, PhD

Study Number: 7910

Phase: Pilot



Laboratory-Treated (Central Memory/Naive) CD8+ T Cells in Treating Patients With Newly Diagnosed or Relapsed Acute Myeloid Leukemia
Complete title: Phase I/II study of Autologous (central memory/naïve) CD8+ T cells that have been transduced to express a WT1-specific T cell receptor for treatment of AML

Principal Investigator: Daniel Egan

Study Number: 9296

Phase: I/II



Pembrolizumab in Treating Minimal Residual Disease in Patients With Acute Lymphoblastic Leukemia
Complete title: A Phase II Study of Anti-PD-1 Antibody (MK-3475; pembrolizumab) for the Treatment of Minimal Residual Disease in Adults with Acute Lymphoblastic Leukemia

Principal Investigator: Ryan Cassaday

Study Number: 9458

Phase: II



Early Allogeneic Hematopoietic Cell Transplantation in Treating Patients With Relapsed or Refractory High-Grade Myeloid Neoplasms
Complete title: A Feasibility Study of 'Early' Allogenic Hematopoietic Cell Transplantation for Relapsed or Refractory High-Grade Myeloid Neoplasm

Principal Investigator: Mary-Elizabeth Percival

Study Number: 9567

Phase: Pilot



Selection of Allogeneic Hematopoietic Cell Donors Based on KIR and HLA Genotypes
Complete title: Selection of Allogeneic Hematopoietic Cell Donors Based on KIR and HLA Genotypes

Principal Investigator: Effie Petersdorf, MD

Study Number: 9577

Phase: Pilot



Immunotherapy After Chemotherapy in Treating Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma
Complete title: A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphomas

Principal Investigator: Mazyar Shadman

Study Number: 9738

Phase: I/II



Higher or Lower Dose Cladribine, Cytarabine, and Mitoxantrone in Treating Medically Less Fit Patients With Newly Diagnosed Acute Myeloid Leukemia or Myeloid Neoplasm
Complete title: Impact of Treatment Intensity on Survival, Quality of Life, and Resource Utilization in Medically Less Fit Adults with Acute Myeloid Leukemia and Analogous Myeloid Neoplasms: A Randomized Pilot Study

Principal Investigator: Anna Halpern

Study Number: 9759

Phase: II



Health Effects After Leukemia Research Study #2 (HEAL-2)

Principal Investigator: Eric Chow, MD

Study Number: HEAL-2

Phase: NA



A Pediatric and Young Adult Trial of Genetically Modified T Cells Directed Against CD19 for Relapsed/Refractory CD19+ Leukemia
Complete title: A Phase 1/2 Feasibility and Safety Study of CD19-CAR T Cell Immunotherapy for CD19+ Leukemia

Principal Investigator: Rebecca Gardner, MD

Study Number: PLAT-02

Phase: I/II



Pilot Study of T-APCs Following CAR T Cell Immunotherapy for CD19+ Leukemia
Complete title: Pediatric and Young Adult Leukemia Adoptive Therapy (PLAT)-03: A Pilot Feasibility and Safety Study of CD19t T-APC Vaccination Following CAR T Cell Immunotherapy for CD19+ Leukemia

Principal Investigator: Colleen Annesley, MD

Study Number: PLAT-03

Phase: Pilot



A Phase 1 Study of CD22 CAR T-Cell Immunotherapy for CD22+ Leukemia (PLAT-04)
Complete title: Pediatric and Young Adult Leukemia Adoptive Therapy (PLAT)-04: A Phase 1 Feasibility and Safety Study of CD22-CAR T Cell Immunotherapy for CD22+ Leukemia

Principal Investigator: Corinne Summers

Study Number: PLAT-04

Phase: I



Different Therapies in Treating Infants With Newly Diagnosed Acute Leukemia (Interfant06)
Complete title: SC-2006. Interfant 06, International Collaborative Treatment Protocol For Infants Under One Year with Acute Lymphoblastic Leukemia or Biphenotypic Leukemia

Principal Investigator: Rebecca Gardner, MD

Study Number: SC-2006

Phase: III



Everolimus With Multiagent Re-Induction Chemotherapy in Pediatric Patients With ALL (CRAD001NUS175T)
Complete title: SC-2015, A Feasibility trial of everolimus (RAD001), an mTOR inhibitor, given in combination with multiagent re-induction in patients with relapsed acute lymphoblastic leukemia (ALL)

Principal Investigator: Todd Cooper

Study Number: SC-2015

Phase: I



Phase I Trial of the Selective Inhibitor of Nuclear Export, KPT-330, in Relapsed Childhood ALL and AML
Complete title: SC-2025, Phase I Trial of the Selective Inhibitor of Nuclear Export, KPT-330, in Relapsed Childhood ALL and AML

Principal Investigator: Todd Cooper

Study Number: SC-2025

Phase: I



Vincristine Sulfate Liposome Injection (Marqibo®) in Combination With UK ALL R3 Induction Chemotherapy for Children, Adolescents, and Young Adults With Relapsed ALL
Complete title: T2012-002: A Pilot Study of Vincristine Sulfate Liposome Injection (Marqibo®) in Combination with UK ALL R3 Induction Chemotherapy for Children, Adolescents, and Young Adults with Relapse of Acute Lymphoblastic Leukemia

Principal Investigator: Todd Cooper

Study Number: T2012-002

Phase: I



Umbilical Cord Blood Transplant, Cyclophosphamide, Fludarabine Phosphate, and Total-Body Irradiation in Treating Patients With Hematologic Disease
Complete title: Transplantation of Umbilical Cord Blood for Patients with Hematological Diseases with Cyclophosphamide/Fludarabine/Total Body Irradiation Myeloablative Preparative Regimen

Principal Investigator: Ann Dahlberg

Study Number: 2010.00

Phase: II



Sirolimus, Cyclosporine, and Mycophenolate Mofetil in Preventing Graft-versus-Host Disease in Treating Patients With Blood Cancer Undergoing Donor Peripheral Blood Stem Cell Transplant
Complete title: A Phase II Study to Assess Immunosuppression with Sirolimus Combined with Cyclosporine (CSP) and Mycophenolate Mofetil (MMF) for Prevention of Acute GVHD after Non-Myeloablative HLA Class I or II Mismatched Donor Hematopoietic Cell Transplantation – A Multi-Center Trial

Principal Investigator: Brenda Sandmaier, MD

Study Number: 2206.00

Phase: II



Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer
Complete title: Transplantation of Umbilical Cord Blood in Patients with Hematological Malignancies Using a Reduced-intensity Preparative Regimen

Principal Investigator: Rachel Salit

Study Number: 2239.00

Phase: II



Autologous Peripheral Blood Stem Cell Transplant Followed by Donor Bone Marrow Transplant in Treating Patients With High-Risk Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Multiple Myeloma, or Chronic Lymphocytic Leukemia
Complete title: Sequential Autologous HCT / Nonmyeloablative Allogeneic HCT using Related, HLA-Haploidentical Donors for Patients with High-Risk Lymphoma, Multiple Myeloma, or Chronic Lymphocytic Leukemia

Principal Investigator: Mohamed Sorror, MD, MSc

Study Number: 2241.00

Phase: II



Treosulfan, Fludarabine Phosphate, and Total-Body Irradiation in Treating Patients With Hematological Cancer Who Are Undergoing Donor Umbilical Cord Blood Transplant
Complete title: Transplantation of Umbilical Cord Blood in Patients with Hematological Malignancies Using a Treosulfan Based Preparative Regimen

Principal Investigator: Filippo Milano

Study Number: 2275.00

Phase: II



Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies
Complete title: Nonmyeloablative Hematopoietic Cell Transplantation (HCT) for Patients with Hematologic Malignancies using Related, HLA-Haploidentical Donors: A Phase II trial of Peripheral Blood Stem Cells (PBSC) as the Donor Source

Principal Investigator: Rachel Salit

Study Number: 2372.00

Phase: II



Donor Atorvastatin Treatment in Preventing Severe Acute GVHD After Nonmyeloablative Peripheral Blood Stem Cell Transplant in Patients With Hematological Malignancies
Complete title: Donor Statin Treatment for Prevention of Severe Acute GVHD after Nonmyeloablative Hematopoietic Cell Transplantation

Principal Investigator: Marco Mielcarek, MD

Study Number: 2546.00

Phase: II



Double Cord Versus Haploidentical (Blood and Marrow Transplant Clinical Trials Network #1101)
Complete title: A Multi-Center, Phase III, Randomized Trial of Reduced Intensity (RIC) Conditioning and Transplantation of Double Unrelated Umbilical Cord Blood (dUCB) versus HLA-Haploidentical Related Bone Marrow for Patients with Hematologic Malignancies

Principal Investigator: Rachel Salit

Study Number: 2580.00

Phase: III



Laboratory Treated T Cells in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma, or Acute Lymphoblastic Leukemia
Complete title: Phase I/II Study of Immunotherapy for Advanced CD19+ Chronic Lymphocytic Leukemia and Non-Hodgkin Lymphoma with Defined Subsets of Autologous T Cells Engineered to Express a CD19-Specific Chimeric Antigen Receptor

Principal Investigator: David Maloney, MD, PhD

Study Number: 2639.00

Phase: I/II



Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts From HLA-Matched Related and Unrelated Donors in Preventing GVHD
Complete title: A Phase II Study Evaluating Selective Depletion of CD45RA+ T Cells from Allogeneic Peripheral Blood Stem Cell Grafts from HLA-Matched Related and Unrelated Donors for Prevention of GVHD

Principal Investigator: Marie Bleakley, MD

Study Number: 2684.00

Phase: II



Brentuximab Vedotin With or Without Nivolumab in Treating Patients With Relapsed or Refractory CD30+ Lymphoma
Complete title: A Pilot Study of Weekly Brentuximab Vedotin or Brentuximab Vedotin Plus Nivolumab Every 3 Weeks in Patients with CD30+ Malignancies Refractory to Every 3 Week Brentuximab Vedotin

Principal Investigator: Ajay Gopal, MD

Study Number: 7808

Phase: II



Telemonitoring Device in Managing Outpatient Care of Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia After Intensive Chemotherapy
Complete title: Integrating a Telemonitoring Device into the Outpatient Management of Adult Patients Following Intensive Chemotherapy for MDS and Non-APL AML: A Randomized Pilot Study

Principal Investigator: Anna Halpern

Study Number: 9105

Phase: Pilot



HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy (RAFA)
Complete title: A Phase II Trial of Hematopoietic Stem Cell Transplantation for the Treatment of Patients with Fanconi Anemia Lacking a Genotypically Identical Donor, Using a Risk-Adjusted Chemotherapy Only Cytoreduction with Busulfan, Cyclophosphamide and Fludarabine

Principal Investigator: K.Scott Baker

Study Number: 9213

Phase: II



High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory Acute Leukemia
Complete title: Individualized Treatment for Relapsed/Refractory Acute Leukemia Based on Chemosensitivity and Genomics/Gene Expression Data

Principal Investigator: Pamela Becker, MD, PhD

Study Number: 9226

Phase: Pilot



Genetically Modified T-Cell Therapy in Treating Patients With Advanced ROR1+ Malignancies
Complete title: Phase I Study of Adoptive Immunotherapy for Advanced ROR1+ Malignancies with Defined Subsets of Autologous T cells Engineered to Express a ROR1-Specific Chimeric Antigen Receptor

Principal Investigator: David Maloney, MD, PhD

Study Number: 9330

Phase: I



huJCAR014 CAR-T Cells in Treating Adult Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma or Acute Lymphoblastic Leukemia
Complete title: A Two-Stage Phase 1 Open-Label Study of huJCAR014, CD19-targeted Chimeric Antigen Receptor (CAR)-Modified T cells Bearing a Human Binding Domain, in Adult Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma and Acute Lymphocytic Leukemia

Principal Investigator: Cameron Turtle, PhD, MBBS

Study Number: 9364

Phase: I



Filgrastim, Cladribine, Cytarabine and Mitoxantrone With Sorafenib Tosylate in Treating Patients With Newly-Diagnosed, Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
Complete title: Addition of Sorafenib to G-CSF, Cladribine, Cytarabine and Mitoxantrone (G-CLAM) in Adults with Newly-Diagnosed Acute Myeloid Leukemia (AML) Independent of FLT3-ITD status: A Phase 1/2 Study

Principal Investigator: Anna Halpern

Study Number: 9510

Phase: I/II



Ixazomib Citrate and Rituximab in Treating Patients With Indolent B-cell Non-Hodgkin Lymphoma
Complete title: A Window Study of Ixazomib in Untreated Indolent B-NHL

Principal Investigator: Ajay Gopal, MD

Study Number: 9571

Phase: II



211^At-BC8-B10 Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndrome
Complete title: A Study Evaluating Escalating Doses of 211At-labeled anti-CD45 MAb BC8-B10 (211At-BC8-B10) followed by Allogeneic Hematopoietic Cell Transplantation for High-Risk Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), or Myelodysplastic Syndrome (MDS)

Principal Investigator: Brenda Sandmaier, MD

Study Number: 9595

Phase: I/II



Decitabine, Filgrastim, Cladribine, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With Newly Diagnosed, Relapsed, or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
Complete title: Randomized Phase 1 Study of Sequential (“Primed”) vs. Concurrent Decitabine in Combination with G-CSF, Cladribine, Cytarabine, and Mitoxantrone (G-CLAM) in Adults with Newly Diagnosed or Relapsed/Refractory Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndromes (MDS)

Principal Investigator: Sarah Buckley

Study Number: 9713

Phase: I



Vaccine Therapy in Reducing the Frequency of Cytomegalovirus Events in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant
Complete title: A Phase II Randomized, Placebo -Controlled, Multicenter Trial to Evaluate Protective Function of an Optimized Dose of CMVPepVax in Recipients of an Allogeneic Hematopoietic Stem Cell Transplant

Principal Investigator: Joshua Hill

Study Number: 9733

Phase: II



Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
Complete title: A Phase II Study of Dose-Adjusted Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) as Front-Line Therapy for Adults with Acute Lymphoblastic Leukemia/Lymphoma

Principal Investigator: Ryan Cassaday

Study Number: 9770

Phase: II



Management of Platelet Transfusion Therapy in Patients With Blood Cancer or Treatment-Induced Thrombocytopenia
Complete title: Management of Acute Venous Thromboembolic Events (VTE) in Patients with Hematologic Disorders and Treatment-Induced Thrombocytopenia: a Pilot Study

Principal Investigator: Bethany Samuelson

Study Number: 9799

Phase: NA



Comparison of Triple GVHD Prophylaxis Regimens for Nonmyeloablative or Reduced Intensity Conditioning Unrelated Mobilized Blood Cell Transplantation
Complete title: A Randomized Phase II Study to Compare the Net Clinical Benefit of Cyclosporine and Sirolimus combined with MMF or Post-Transplant Cyclophosphamide as GVHD Prophylaxis after HLA-Matched or HLA-Mismatched Unrelated G-CSF Mobilized Blood Cell Transplantation using Nonmyeloablative or Reduced Intensity Conditioning for Patients with Hematologic Malignancies: A Multi-Center Trial

Principal Investigator: Masumi Ueda

Study Number: 9816

Phase: II



A Pilot RCT of the PRISM Intervention for AYAs With Cancer
Complete title: A Pilot Randomized Controlled Trial of the Promoting Resilience in Stress Management (PRISM) Intervention for Adolescents and Young Adults with Cancer

Principal Investigator: Abby Rosenberg

Study Number: SC-N114

Phase: Pilot



A Trial of Temsirolimus With Etoposide and Cyclophosphamide in Children With Relapsed Acute Lymphoblastic Leukemia and Non-Hodgkins Lymphoma
Complete title: TACL 2014-001: A Phase I Trial of Temsirolimus (CCI-779, Pfizer, Inc.) in Combination with Etoposide and Cyclophosphamide in Children with Relapsed Acute Lymphoblastic Leukemia and Non-Hodgkin Lymphoma.

Principal Investigator: Todd Cooper

Study Number: TACL 2014-001

Phase: I



Collecting and Storing Samples of Bone Marrow and Blood From Patients With Relapsed Acute Lymphoblastic Leukemia or Non-Hodgkin Lymphoma
Complete title: AALL05B1, A Children's Oncology Group Protocol for the Collecting and Banking of Relapsed Acute Lymphoblastic Leukemias

Principal Investigator: Doug Hawkins, MD

Study Number: AALL05B1



Risk-Based Classification System of Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
Complete title: AALL08B1, Classification of Newly Diagnosed Acute Lymphoblastic Leukemia (ALL).

Principal Investigator: Doug Hawkins, MD

Study Number: AALL08B1



Risk-Adapted Chemotherapy in Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia
Complete title: AALL0932, Treatment of Patients with Newly Diagnosed Standard Risk B-Precursor Acute Lymphoblastic Leukemia (ALL).

Principal Investigator: Doug Hawkins, MD

Study Number: AALL0932

Phase: III



Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia
Complete title: AALL1131: A Phase III Randomized Trial for Newly Diagnosed High Risk B-precursor Acute Lymphoblastic Leukemia (ALL) Testing Clofarabine (IND# 73789, NSC# 606869) in the Very High Risk Stratum

Principal Investigator: Doug Hawkins, MD

Study Number: AALL1131

Phase: III



Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma
Complete title: AALL1231, A Phase III Randomized Trial Investigating Bortezomib (NSC# 681239; IND# 58443) on a Modified Augmented BFM (ABFM) Backbone in Newly Diagnosed T- Lymphoblastic Leukemia (T-ALL) and T- Lymphoblastic Lymphoma (T-LLy)

Principal Investigator: Kasey Leger, MD

Study Number: AALL1231

Phase: III



Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia
Complete title: AALL1331 Risk-Stratified Randomized Phase III Testing of Blinatumomab (IND#117467, NSC#765986) in First Relapse of Childhood B-Lymphoblastic Leukemia (B-ALL)

Principal Investigator: Rebecca Gardner, MD

Study Number: AALL1331

Phase: III



A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic Leukemia
Complete title: AALL1521 INCB 18424-269 A Phase 2 Study of the JAK1/JAK2 Inhibitor Ruxolitinib With Chemotherapy in Children with De Novo High-Risk CRLF2-Rearranged and/or JAK Pathway –Mutant Acute Lymphoblastic Leukmia

Principal Investigator: Colleen Annesley, MD

Study Number: AALL1521

Phase: II



Tretinoin and Arsenic Trioxide in Treating Patients With Untreated Acute Promyelocytic Leukemia
Complete title: A Phase III Study for Patients with Newly Diagnosed Acute Promyelocytic Leukemia (APL) using Arsenic Trioxide and All-Trans Retinoic Acid

Principal Investigator: Todd Cooper

Study Number: AAML1331

Phase: III



Liposomal Cytarabine-Daunorubicin CPX-351, Fludarabine Phosphate, Cytarabine, and Filgrastim in Treating Younger Patients With Relapsed or Refractory Acute Myeloid Leukemia
Complete title: A Phase 1/2 Study of CPX-351 (NSC# 775341; IND #129443) Alone Followed by Fludarabine, Cytarabine, and G-CSF (FLAG) for Children with Relapsed Acute Myeloid Leukemia

Principal Investigator: Todd Cooper

Study Number: AAML1421

Phase: I/II



Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome in Younger Patients With Down Syndrome
Complete title: Risk-Stratified Therapy for Acute Myeloid Leukemia in Down Syndrome

Principal Investigator: Todd Cooper

Study Number: AAML1531

Phase: III



Assessing Compliance With Mercaptopurine Treatment in Younger Patients With Acute Lymphoblastic Leukemia in First Remission
Complete title: ACCL1033, A Comprehensive Approach to Improve Medication Adherence in Pediatric ALL

Principal Investigator: Eric Chow, MD

Study Number: ACCL1033

Phase: NA



Enrollment on the Childhood Cancer Research Network (CCRN) of the Children s Oncology Group
Complete title: ACCRN07, Protocol for the Enrollment on the Official COG Registry, The Childhood Cancer Research Network (CCRN) and Local Data Collection

Principal Investigator: Doug Hawkins, MD

Study Number: ACCRN07



Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas
Complete title: A Phase 1/2 Study of Nivolumab (IND#124729) in Children, Adolescents, and Young Adults with Recurrent or Refractory Solid Tumors as a Single Agent and in Combination with Ipilimumab

Principal Investigator: Julie Park, MD

Study Number: ADVL1412

Phase: I/II



Safety Study of Anti-LAG-3 in CLL, HL and NHL
Complete title: A Phase 1 Dose Escalation and Cohort Expansion Study of the Safety, Tolerability, and Efficacy of Anti-LAG-3 (BMS-986016) in Relapsed or Refractory Chronic Lymphocytic Leukemia and Lymphomas

Principal Investigator: Ajay Gopal, MD

Study Number: 20132238

Phase: I



Phase 1b Acute Myelogenous Leukemia (AML) Study With ABT-199 + Decitabine or Azacitidine (Chemo Combo)
Complete title: A Phase 1b Study of ABT-199 (GDC-0199) in Combination with Azacitidine or Decitabine in Treatment Naïve Subjects with Acute Myelogenous Leukemia Who Are = 65 Years of Age and Who Are Not Eligible for Standard Induction Therapy

Principal Investigator: Pamela Becker, MD, PhD

Study Number: 20141655

Phase: I/II



Study to Determine Safety, Pharmacokinetics and Efficacy of GMI-1271 in Combination With Chemotherapy in AML
Complete title: A Phase I/II, open-label multi-center study to determine safety, pharmacokinetics and efficacy of GMI-1271 in combination with chemotherapy in patients with acute myeloid leukemia

Principal Investigator: Pamela Becker, MD, PhD

Study Number: 20150436

Phase: I/II



Safety and Efficacy of Entospletinib With Vincristine and Dexamethasone in Adults With Relapsed or Refractory Acute Lymphoid Leukemia (ALL)
Complete title: A Phase 1b, Open-Label, Dose Escalation and Expansion Study Evaluating the Safety and Efficacy of Entospletinib (GS-9973) with Vincristine and Dexamethasone in Adult Subjects with Relapsed or Refractory Acute Lymphoid Leukemia (ALL)

Principal Investigator: Ryan Cassaday

Study Number: 20150518

Phase: I



An Open-Label, Dose-Escalation Study of INCB054329 in Patients With Advanced Malignancies
Complete title: Phase 1, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCB054329 in Subjects with Advanced Malignancies

Principal Investigator: Ryan Cassaday

Study Number: 20152763

Phase: I



Study to Assess the Efficacy and Safety of Ublituximab + TGR-1202 With or Without Bendamustine and TGR-1202 Alone in Patients With Previously Treated Non-Hodgkins Lymphoma (UNITY-NHL)
Complete title: A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR-1202 with or without Bendamustine and TGR-1202 alone in Patients with Previously Treated Non- Hodgkin’s Lymphoma

Principal Investigator: Ajay Gopal, MD

Study Number: 20161033

Phase: II



Phase 1/2A Dose Escalation Study in CLL, SLL or NHL
Complete title: A PHASE 1/2A OPEN-LABEL, MULTI-DOSE, MULTI-CENTER ESCALATION AND EXPLORATORY STUDY OF CERDULATINIB (PRT062070) IN PATIENTS WITH RELAPSED/ REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)/ SMALL LYMPHOCYTIC LYMPHOMA (SLL) OR B-CELL OR T-CELL NON-HODGKIN LYMPHOMA (NHL)

Principal Investigator: Stephen Smith

Study Number: 20170188

Phase: I/II



Clinical Study of CWP232291 in Acute Myeloid Leukemia Patients
Complete title: A Phase 1b Clinical Study of CWP232291 in Combination with Cytarabine in Subjects with Relapsed or Refractory Acute Myeloid Leukemia (AML)

Principal Investigator: Pamela Becker, MD, PhD

Study Number: 20170427

Phase: I



Low Dose Cytarabine and Lintuzumab-Ac225 in Older AML Patients
Complete title: A Phase I/II Study of Lintuzumab-Actinium-225 in Older Patients with Untreated Acute Myeloid Leukemia (AML)

Principal Investigator: Johnnie Orozco, MD, PhD

Study Number: 2572.00

Phase: I/II



ety Study of Gene Modified Donor T-cells Following Partially Mismatched Stem Cell Transplant
Complete title: A Phase1/2 Dose Escalation Study Evaluating Safety and Feasibility of BPX-501 T Cells after Partially Mismatched, Related, T Cell-Depleted HSCT

Principal Investigator: Brenda Sandmaier, MD

Study Number: 2653.00

Phase: I



Safety Study of Gene Modified Donor T-cells Following TCR Alpha Beta Depleted Stem Cell Transplant
Complete title: Phase 1/2 Study of CaspaCide T Cells from an HLA-Partially Matched Family Donor after Negative Selection of TCR aß+ T Cells in Pediatric Patients Affected by Hematological Disorders

Principal Investigator: Lauri Burroughs, MD

Study Number: 9311

Phase: I/II



A Phase 1 Study of AMG 330 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia
Complete title: A Phase 1 First-In-Human Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of AMG 330 Administered as Continuous Intravenous Infusion in Subjects with Relapsed/Refractory Acute Myeloid Leukemia

Principal Investigator: Roland Walter, MD

Study Number: 9382

Phase: I



SL-401 as Consolidation Therapy in Patients With Adverse Risk Acute Myeloid Leukemia in First Complete Remission
Complete title: A Phase 1/2 Study of SL-401 as Consolidation Therapy for Adult Patients with Adverse Risk Acute Myeloid Leukemia in First CR, and/or Evidence of Minimal Residual Disease (MRD) in First CR

Principal Investigator: Roland Walter, MD

Study Number: 9498

Phase: I/II



A Phase 1/2, Open-label, Dose Finding Study to Evaluate CC-122 in Combination With Ibrutinib and Obinutuzumab in Subjects With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (ENHANCE)
Complete title: Phase 1/2 Study to Determine the Safety, Pharmacokinetics, and Efficacy of Single Agent CC 122 and the Combinations of CC-122 and Ibrutinib and CC-122 and Obinutuzumab in Subjects with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Principal Investigator: Mazyar Shadman

Study Number: 9597

Phase: I/II



Study of Iomab-B Prior to HCT vs. Conventional Care in Older Subjects With Active, Relapsed or Refractory AML (SIERRA)
Complete title: IOMAB-01: A Multicenter, Pivotal Phase 3 Study of Iomab-B Prior to Allogeneic Hematopoietic Cell Transplantation versus Conventional Care in Older Subjects with Active, Relapsed or Refractory Acute Myeloid Leukemia

Principal Investigator: Johnnie Orozco, MD, PhD

Study Number: 9645

Phase: III



A Safety Study of SGN-CD123A in Patients With Acute Myeloid Leukemia
Complete title: A Phase 1 Study of SGN-CD123A in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML)

Principal Investigator: Roland Walter, MD

Study Number: 9653

Phase: I



An Open-Label Study to Evaluate the Safety and Efficacy of Ublituximab in Combination With TGR-1202 for Patients Previously Enrolled in Protocol UTX-TGR-304
Complete title: A Mutli-Center, Open Label, Compassionate Use Extension study of Ublituximab (TG-1101) in Combination with TGR-1202 for Patients Previously Enrolled in Protocol UTX-TGR-304

Principal Investigator: Mazyar Shadman

Study Number: 9703

Phase: III



Guadecitabine (SGI-110) vs Treatment Choice in Adults With MDS or CMML Previously Treated With HMAs
Complete title: A Phase 3, Multicenter, Randomized, Open-label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML) Previously Treated with Hypomethylating Agents

Principal Investigator: Bart Scott, MD

Study Number: 9723

Phase: III



Study of Pembrolizumab in Combination With Ublituximab and TGR-1202 in Patients With Relapsed-refractory CLL
Complete title: Phase I/II Study of Pembrolizumab in Combination with TG-1101 (Ublituximab) and TGR-1202 in Patients with Relapsed-Refractory CLL or Richter’s Transformation of CLL

Principal Investigator: Mazyar Shadman

Study Number: 9727

Phase: I/II



Phase 1 Trial to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of Splicing Modulator H3B-8800 for Subjects With Myelodysplastic Syndromes, Acute Myeloid Leukemia, and Chronic Myelomonocytic Leukemia
Complete title: An Open-label, Multicenter Phase 1 Trial to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of Splicing Modulator H3B-8800 for Subjects With Myelodysplastic Syndromes, Acute Myeloid Leukemia, and Chronic Myelomonocytic Leukemia

Principal Investigator: Joachim Deeg, MD

Study Number: 9781

Phase: I



A Safety and Pharmacokinetic Study of BTCT4465A, With or Without Single-dose Obinutuzumab Pretreatment, in Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)
Complete title: An Open-Label, Multicenter, Phase I Trial Evaluating the Safety and Pharmacokinetics of Escalating Doses Of BTCT4465A, With or Without Single Dose Obinutuzmab Pre-Treatment, in Patients with Relapsed or Refractory B-cell Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia

Principal Investigator: Mazyar Shadman

Study Number: 9837

Phase: I



Study of CLR 131 in Relapsed or Refractory Select B-Cell Malignancies
Complete title: An Open-Label, Multicenter, Phase 2 Study of CLR 131 in Patients with Relapsed or Refractory (R/R) Select B-Cell Malignancies

Principal Investigator: Damian Green, MD

Study Number: 9847

Phase: II



A Study Comparing BGB-3111 With Bendamustine Plus Rituximab in Patients With Previously Untreated CLL or SLL
Complete title: An International, Phase 3, Open-label, Randomized Study of BGB-3111 Compared with Bendamustine plus Rituximab in Patients with Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Principal Investigator: Mazyar Shadman

Study Number: 9905

Phase: III



Dasatinib in Combination With Chemotherapy for Relapsed or Refractory Core Binding Factor Acute Myeloid Leukemia
Complete title: SC-2026 Dasatinib in Combination with Chemotherapy for Relapsed or Refractory Core Binding Factor Acute Myeloid Leukemia: A Phase I Study (AflacLL1401)

Principal Investigator: Todd Cooper

Study Number: SC-2026

Phase: I



Panobinostat With Fludarabine and Cytarabine for Treatment of Children With Acute Myeloid Leukemia or Myelodysplastic Syndrome
Complete title: PANAML: A Phase I and Dose Expansion Cohort Study of Panobinostat in Combination with Fludarabine and Cytarabine in Pediatric Patients with Refractory or Relapsed Acute Myeloid Leukemia or Myelodysplastic Syndrome

Principal Investigator: Todd Cooper

Study Number: SC-2029

Phase: I



Search all clinical trials

Select a disease from the list below:

Limit results to studies enrolling:

OR

Search by Keyword, Investigator Name or Study ID#:

Limit results to studies enrolling:

OR

View all studies

Limit results to studies enrolling:

Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.

Please remember:

  • Talk to your health care providers first before making decisions about your health care.
  • Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each study.

Subscribe to an RSS feed of all trials